{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:23:48Z","timestamp":1787311428766,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T00:00:00Z","timestamp":1446422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T00:00:00Z","timestamp":1446422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tissue plasminogen activator (tPA) is the only approved thrombolytic therapy for acute ischemic stroke, yet many patients do not recanalize. Enhancing thrombolytic efficacy of tPA is a major focus of stroke research. Traditionally, a \u201crat dose\u201d of 10\u2009mg\/kg has been used in rodent models. Recent studies suggested that the clinical \u201chuman\u201d dose (0.9\u2009mg\/kg) may better mimic clinical recanalization. These studies only compared the rat and clinical doses and so we aimed to test recanalization efficacy of multiple tPA doses ranging from 0.9 to 10\u2009mg\/kg in a model of endothelial injury and vessel stenosis. The common carotid artery of rats was crushed and stenosed to allow\n                    <jats:italic>in-situ<\/jats:italic>\n                    occlusive thrombus formation (Folt\u2019s model of \u2018physiological\u2019 thrombus). Intravenous tPA was administered 60 minutes post-occlusion (n\u2009=\u20096-7\/group). Sustained recanalization rates were 0%, 17%, 67% and 71%, for 0.9, 1.8, 4.5 and 10\u2009mg\/kg, respectively. Median time to sustained recanalization onset decreased with increasing dosage. We conclude that 10\u2009mg\/kg of tPA is too effective, whereas 0.9\u2009mg\/kg is ineffective for lysis of occlusive thrombi formed\n                    <jats:italic>in situ<\/jats:italic>\n                    . Neither dose mimics clinical tPA responses. A dose of 2x the clinical dose is a more appropriate mimic of clinical tPA recanalization in this model.\n                  <\/jats:p>","DOI":"10.1038\/srep16026","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T06:11:00Z","timestamp":1446444660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tissue Plasminogen Activator for preclinical stroke research: Neither \u201crat\u201d nor \u201chuman\u201d dose mimics clinical recanalization in a carotid occlusion model"],"prefix":"10.1038","volume":"5","author":[{"given":"Amelia J.","family":"Tomkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"BFsrep16026_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1161\/01.STR.0000258112.14918.24","volume":"38","author":"JH Rha","year":"2007","unstructured":"Rha, J. H. & Saver, J. L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38, 967\u2013973 (2007).","journal-title":"Stroke"},{"key":"BFsrep16026_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1552-6569.2002.tb00107.x","volume":"12","author":"I Christou","year":"2002","unstructured":"Christou, I. et al. Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion. J Neuroimaging 12, 119\u2013123 (2002).","journal-title":"J Neuroimaging"},{"key":"BFsrep16026_CR3","doi-asserted-by":"publisher","first-page":"e55318","DOI":"10.1371\/journal.pone.0055318","volume":"8","author":"R Pechlaner","year":"2013","unstructured":"Pechlaner, R. et al. Recanalization of extracranial internal carotid artery occlusion after i.v. thrombolysis for acute ischemic stroke. PLoS One 8, e55318 (2013).","journal-title":"PLoS One"},{"key":"BFsrep16026_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/STROKEAHA.109.563304","volume":"41","author":"G Tsivgoulis","year":"2010","unstructured":"Tsivgoulis, G. et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 41, 280\u2013287 (2010).","journal-title":"Stroke"},{"key":"BFsrep16026_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1055\/s-0038-1653411","volume":"46","author":"C Korninger","year":"1981","unstructured":"Korninger, C. & Collen, D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46, 561\u2013565 (1981).","journal-title":"Thromb Haemost"},{"key":"BFsrep16026_CR6","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/jcbfm.2010.33","volume":"30","author":"B Haelewyn","year":"2010","unstructured":"Haelewyn, B., Risso, J. J. & Abraini, J. H. Human recombinant tissue-plasminogen activator (alteplase): why not use the \u2018human\u2019 dose for stroke studies in rats? J Cereb Blood Flow Metab 30, 900\u2013903 (2010).","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFsrep16026_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.expneurol.2012.08.005","volume":"238","author":"M El Amki","year":"2012","unstructured":"El Amki, M. et al. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke. Exp Neurol 238, 138\u2013144 (2012).","journal-title":"Exp Neurol"},{"key":"BFsrep16026_CR8","unstructured":"U.S. department of Health and Human Services, Food and drug administration. Centre for drug Evaluation and Research (CDER). Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Pharmacology and Toxicology (2005)."},{"key":"BFsrep16026_CR9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/01.STR.0000080941.73934.30","volume":"34","author":"F Niessen","year":"2003","unstructured":"Niessen, F., Hilger, T., Hoehn, M. & Hossmann, K. A. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 34, 2019\u20132024 (2003).","journal-title":"Stroke"},{"key":"BFsrep16026_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0268-9499(93)90013-L","volume":"7","author":"K Overgaard","year":"1993","unstructured":"Overgaard, K. et al. Composition of emboli influences the efficacy of thrombolysis with rt-PA in a rat stroke model. Fibrinolysis 7, 141\u2013148 (1993).","journal-title":"Fibrinolysis"},{"key":"BFsrep16026_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0006-8993(97)01008-1","volume":"778","author":"E Busch","year":"1997","unstructured":"Busch, E., Kruger, K. & Hossmann, K. A. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 778, 16\u201324 (1997).","journal-title":"Brain Res"},{"key":"BFsrep16026_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.brainres.2010.07.050","volume":"1354","author":"KZ Guluma","year":"2010","unstructured":"Guluma, K. Z. & Lapchak, P. A. Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke. Brain Res 1354, 206\u2013216 (2010).","journal-title":"Brain Res"},{"key":"BFsrep16026_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0531-5131(03)00066-9","volume":"1252","author":"S Okubo","year":"2003","unstructured":"Okubo, S. et al. Therapeutic time window of rt-PA on embolic stroke in rats. Int Congress Series 1252, 203\u2013207 (2003).","journal-title":"Int Congress Series"},{"key":"BFsrep16026_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0268-9499(98)80383-4","volume":"12","author":"L Calandre","year":"1998","unstructured":"Calandre, L., Grau, M. & Cabello, A. Lysis rates with rt-PB vary between different human emboli in a rat model of cerebral embolism. Fibrinolysis & Proteolysis 12, 107\u2013111 (1998).","journal-title":"Fibrinolysis & Proteolysis"},{"key":"BFsrep16026_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1161\/01.STR.0000173161.05453.90.9f","volume":"36","author":"M Ribo","year":"2005","unstructured":"Ribo, M. et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 36, 1705\u20131709 (2005).","journal-title":"Stroke"},{"key":"BFsrep16026_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/01.STR.0000257314.74853.2b","volume":"38","author":"G Tsivgoulis","year":"2007","unstructured":"Tsivgoulis, G. et al. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke 38, 961\u2013966 (2007).","journal-title":"Stroke"},{"key":"BFsrep16026_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.vascn.2005.06.006","volume":"53","author":"SA Sturgeon","year":"2006","unstructured":"Sturgeon, S. A., Jones, C., Angus, J. A. & Wright, C. E. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. J Pharmacol Toxicol Methods 53, 20\u201329 (2006).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"BFsrep16026_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jneumeth.2014.08.025","volume":"237","author":"FC Roessler","year":"2014","unstructured":"Roessler, F. C. et al. Development of a new clot formation protocol for standardized in vitro investigations of sonothrombolysis. J Neurosci Methods 237, 26\u201332 (2014).","journal-title":"J Neurosci Methods"},{"key":"BFsrep16026_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/01.ATV.21.1.142","volume":"21","author":"JP Collet","year":"2001","unstructured":"Collet, J. P. et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21, 142\u2013148 (2001).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFsrep16026_CR20","doi-asserted-by":"publisher","first-page":"IV26","DOI":"10.1161\/01.CIR.83.1.26","volume":"83","author":"HK Gold","year":"1991","unstructured":"Gold, H. K. et al. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. Circulation 83, IV26\u201340 (1991).","journal-title":"Circulation"},{"key":"BFsrep16026_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13231-014-0014-y","volume":"7","author":"AJ Tomkins","year":"2015","unstructured":"Tomkins, A. J. et al. Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke. Exp Transl Stroke Med 7, 2 (2015).","journal-title":"Exp Transl Stroke Med"},{"key":"BFsrep16026_CR22","first-page":"1905","volume":"30","author":"ES Sena","year":"2010","unstructured":"Sena, E.S. et al. Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. JCBFM 30, 1905\u20131913 (2010).","journal-title":"JCBFM"},{"key":"BFsrep16026_CR23","unstructured":"National Health and Medical Research Council (NHMRC). Australian code for the care and use of animals for scientific purposes, 8th edition. Canberra: National Health and Medical Research Council (2013)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep16026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16026","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T08:36:50Z","timestamp":1672907810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep16026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,21]]}},"alternative-id":["BFsrep16026"],"URL":"https:\/\/doi.org\/10.1038\/srep16026","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]},"assertion":[{"value":"27 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16026"}}